The literature on non-profit pharmaceutical research and development (R&D) initiatives, such as product development partnerships for neglected diseases, has established that they are able to develop safe, effective products successfully. However, much less attention has been paid to whether and how patient access to such products can be delivered, in light of key differences with mainstream commercial incentives for marketing, distributing and selling new medicines.